发布求助
文献互助 智能选刊 最新文献

Global and Regional Health Technology Assessment最新文献

筛选
英文 中文
The Promotion of Drug Innovation in Italy: Critical Aspects and Unsolved Problems 促进意大利的药物创新:关键方面和未解决的问题
Global and Regional Health Technology Assessment Pub Date : 2016-02-11 DOI: 10.5301/GRHTA.5000216
F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti
{"title":"The Promotion of Drug Innovation in Italy: Critical Aspects and Unsolved Problems","authors":"F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti","doi":"10.5301/GRHTA.5000216","DOIUrl":"https://doi.org/10.5301/GRHTA.5000216","url":null,"abstract":"The pharmaceutical sector is characterized by the level of investments required in response to the growing challenges in terms of demand for health.In most European countries the pharmaceutical industry, through production, research, intermediate goods and wages, contributes to GDP for a value of about 1%. The impact of the pharmaceutical industry on the added value varies from 23 billion euro in Switzerland to 9.6 billion euro in Spain; for Italy, this value is about 14 billion euro, higher than the average of other European countries.However, despite these positive findings, Italy can hardly keep up with other European countries in investments in R&D in the pharmaceutical sector.An even larger amount of resources is required by the development of personalized therapies and new generation drugs, e.g. developed through biotechnology, which are more effective in responding to complex health needs. Clear rules, aimed at defining and fostering innovation, together with competitive pricing models, are require...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127718818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Real World Data use and Applications in the Integrated Management of Rheumatic Disease 风湿病综合管理中的真实世界数据使用和应用
Global and Regional Health Technology Assessment Pub Date : 2015-11-19 DOI: 10.5301/GRHTA.5000212
P. Berto, S. Adami, C. Botsios, Valentina Fantelli, A. M. Grion, F. Ometto, L. Punzi, Chiara Roni, G. Scroccaro
{"title":"Real World Data use and Applications in the Integrated Management of Rheumatic Disease","authors":"P. Berto, S. Adami, C. Botsios, Valentina Fantelli, A. M. Grion, F. Ometto, L. Punzi, Chiara Roni, G. Scroccaro","doi":"10.5301/GRHTA.5000212","DOIUrl":"https://doi.org/10.5301/GRHTA.5000212","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"227 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115517483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
14° Convegno Nazionale Economia e Politica del Farmaco e delle Tecnologie Sanitarie Novara, 23 Giugno 2015 2015年6月23日，诺瓦拉
Global and Regional Health Technology Assessment Pub Date : 2015-11-06 DOI: 10.5301/grhta.2015.14791
   
{"title":"14° Convegno Nazionale Economia e Politica del Farmaco e delle Tecnologie Sanitarie Novara, 23 Giugno 2015","authors":"   ","doi":"10.5301/grhta.2015.14791","DOIUrl":"https://doi.org/10.5301/grhta.2015.14791","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122000980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit 阿瑞吡坦与标准治疗(5-HT3 +皮质类固醇)相比预防高致吐性化疗引起的恶心和呕吐的成本-后果分析
Global and Regional Health Technology Assessment Pub Date : 2015-10-07 DOI: 10.5301/GRHTA.5000195
R. Ravasio, G. Rosti
{"title":"Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit","authors":"R. Ravasio, G. Rosti","doi":"10.5301/GRHTA.5000195","DOIUrl":"https://doi.org/10.5301/GRHTA.5000195","url":null,"abstract":"IntroductionPrevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving cytotoxic treatment. The objective of this study was to assess, from the I...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131352324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Cost-Effectiveness Analysis of Long-Acting Bronchodilators for the Treatment of COPD (Moderate to Very Severe) 长效支气管扩张剂治疗慢性阻塞性肺病(中度至极重度)的成本-效果分析
Global and Regional Health Technology Assessment Pub Date : 2015-09-30 DOI: 10.5301/GRHTA.5000204
R. Ravasio
{"title":"Cost-Effectiveness Analysis of Long-Acting Bronchodilators for the Treatment of COPD (Moderate to Very Severe)","authors":"R. Ravasio","doi":"10.5301/GRHTA.5000204","DOIUrl":"https://doi.org/10.5301/GRHTA.5000204","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127579122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries 创新与药品价格和报销:意大利与其他欧盟主要国家的比较
Global and Regional Health Technology Assessment Pub Date : 2015-09-24 DOI: 10.5301/GRHTA.5000206
C. Jommi
{"title":"Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries","authors":"C. Jommi","doi":"10.5301/GRHTA.5000206","DOIUrl":"https://doi.org/10.5301/GRHTA.5000206","url":null,"abstract":"This paper aims at investigating (i) differences and commonalities of drugs Price and Reimbursement (P&R) criteria between Italy and the other major EU countries and (ii) comparative advantages, pi...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116251356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Economic Analysis of the Immunostimulant OM-85 for the Prevention of Paediatric Recurrent Upper Respiratory Tract Infections 免疫刺激剂OM-85预防小儿反复上呼吸道感染的经济分析
Global and Regional Health Technology Assessment Pub Date : 2015-09-17 DOI: 10.5301/GRHTA.5000200
R. Ravasio
{"title":"Economic Analysis of the Immunostimulant OM-85 for the Prevention of Paediatric Recurrent Upper Respiratory Tract Infections","authors":"R. Ravasio","doi":"10.5301/GRHTA.5000200","DOIUrl":"https://doi.org/10.5301/GRHTA.5000200","url":null,"abstract":"Objective: To evaluate the cost of preventing recurrent upper respiratory tract infections (URTIs) with a non- specific immunostimulating agent (OM-85) in at-risk children. Methods: A cost consequence analysis was conducted considering three different perspectives: Community, National Health Service and patient. A pre-existing decisional model was used to compare prophylaxis with OM-85 and no prophylaxis. The clinical data was based on the weighted average of the results of nine randomized pla-cebo-controlled trials identified by a Cochrane literature review. Clinical events considered in the model were natural resolution of the infection, onset of complications (acute otitis media, sinusitis, others) and their evolu-tion. Direct and indirect costs incurred by patient, NHS and Community were structured in accordance with the most authoritative guidelines and implemented with current Italian prices and tariffs. Sensibility analyses were performed to evaluate the model robustness. Results: The immunostimulating agent OM-85 achieved savings for 40.30 euro/patient in the perspective of the National Health Service and for 182.99 euro/patient in the community’s perspective. Sensitivity analyses con-firmed the robustness of base scenario results. Conclusions: Non-specific immunotherapy with OM-85 reduces the incidence of URTIs in at-risk children to-gether with savings for the community and NHS.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131775305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Therapeutic continuity in the treatment of psychiatric disorders 精神疾病治疗的连续性
Global and Regional Health Technology Assessment Pub Date : 2015-07-10 DOI: 10.5301/GRHTA.5000197
S. L. Pia, C. Mencacci, M. Pani, E. Spina, A. Vercellone
{"title":"Therapeutic continuity in the treatment of psychiatric disorders","authors":"S. L. Pia, C. Mencacci, M. Pani, E. Spina, A. Vercellone","doi":"10.5301/GRHTA.5000197","DOIUrl":"https://doi.org/10.5301/GRHTA.5000197","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124852799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective 为创新买单的意愿:从意大利国家卫生服务体系的角度看抗丙型肝炎病毒药物的案例
Global and Regional Health Technology Assessment Pub Date : 2015-07-10 DOI: 10.5301/GRHTA.5000201
F. Mennini, A. Marcellusi, R. Viti, M. Andreoni
{"title":"Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective","authors":"F. Mennini, A. Marcellusi, R. Viti, M. Andreoni","doi":"10.5301/GRHTA.5000201","DOIUrl":"https://doi.org/10.5301/GRHTA.5000201","url":null,"abstract":"getti con una positività ematica all’HCV RNA è generalmente superiore al 3% nei nati prima del 1950 e aumenta progressivamente con l’età, mentre è considerevolmente più bassa, in assenza di tossicodipendenza, nelle generazioni più giovani (1). Il problema dell’infezione da HCV risiede nella possibile evoluzione clinica che si manifesta nel soggetto infetto nel medio/lungo periodo. Nel corso degli anni, infatti, l’HCV cronica può portare alla cirrosi epatica e, infine, alla morte. L’HCV è una malattia asintomatica e, come tale, viene trattata principalmente in una fase avanzata (1). Tra i pazienti che acquisiscono l’infezione da HCV, infatti, oltre il 90% diventa portatore cronico, sviluppando nel 65-95% dei casi un’epatopatia cronica e nel 10-30% dei casi un rischio di evolvere in cirrosi nell’arco di 25-30 anni (2). I soggetti cirrotici a loro volta hanno una probabilità per anno dell’1-3% di sviluppare DOI: 10.5301/GRHTA.5000201","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125078606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Therapeutic Value and Innovation of a Drug and Criteria for Evaluation: A Multidisciplinary Experience in the Veneto Region 药物的治疗价值和创新以及评价标准:威尼托地区的多学科经验
Global and Regional Health Technology Assessment Pub Date : 2015-07-10 DOI: 10.5301/GRHTA.5000196
S. Adami, A. Alberti, M. Andretta, G. Buzzetti, E. Bonora, Nicola Braggio, M. Cancian, E. Concia, P. Conte, M. Boni, V. Fadda, A. Ferrarese, B. Giometto, R. Leone, V. Pengo, P. Pertile, L. Punzi, M. Saugo, G. Scroccaro, A. Vianello
{"title":"Therapeutic Value and Innovation of a Drug and Criteria for Evaluation: A Multidisciplinary Experience in the Veneto Region","authors":"S. Adami, A. Alberti, M. Andretta, G. Buzzetti, E. Bonora, Nicola Braggio, M. Cancian, E. Concia, P. Conte, M. Boni, V. Fadda, A. Ferrarese, B. Giometto, R. Leone, V. Pengo, P. Pertile, L. Punzi, M. Saugo, G. Scroccaro, A. Vianello","doi":"10.5301/GRHTA.5000196","DOIUrl":"https://doi.org/10.5301/GRHTA.5000196","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122269448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信